Raltegravir  ||| S:0 E:12 ||| JJ
use  ||| S:12 E:16 ||| NN
in  ||| S:16 E:19 ||| IN
special  ||| S:19 E:27 ||| JJ
populations  ||| S:27 E:39 ||| JJ
Raltegravir ||| S:39 E:50 ||| NNP
,  ||| S:50 E:52 ||| ,
the  ||| S:52 E:56 ||| DT
first  ||| S:56 E:62 ||| JJ
approved  ||| S:62 E:71 ||| VBN
integrase  ||| S:71 E:81 ||| JJ
inhibitor ||| S:81 E:90 ||| NN
,  ||| S:90 E:92 ||| ,
has  ||| S:92 E:96 ||| VBZ
been  ||| S:96 E:101 ||| VBN
shown  ||| S:101 E:107 ||| VBN
to  ||| S:107 E:110 ||| TO
be  ||| S:110 E:113 ||| VB
virologically  ||| S:113 E:127 ||| JJ
effective  ||| S:127 E:137 ||| JJ
in  ||| S:137 E:140 ||| IN
Phase  ||| S:140 E:146 ||| NNP
II  ||| S:146 E:149 ||| NNP
and  ||| S:149 E:153 ||| CC
Phase  ||| S:153 E:159 ||| NNP
III  ||| S:159 E:163 ||| NNP
clinical  ||| S:163 E:172 ||| JJ
trials  ||| S:172 E:179 ||| NNS
in  ||| S:179 E:182 ||| IN
both  ||| S:182 E:187 ||| DT
treatment  ||| S:187 E:197 ||| NN
naive  ||| S:197 E:203 ||| NNS
and  ||| S:203 E:207 ||| CC
triple  ||| S:207 E:214 ||| JJ
class  ||| S:214 E:220 ||| NN
resistant  ||| S:220 E:230 ||| JJ
patients ||| S:230 E:238 ||| NNS
.  ||| S:238 E:240 ||| .
It  ||| S:240 E:243 ||| PRP
also  ||| S:243 E:248 ||| RB
has  ||| S:248 E:252 ||| VBZ
an  ||| S:252 E:255 ||| DT
excellent  ||| S:255 E:265 ||| JJ
tolerability  ||| S:265 E:278 ||| JJ
profile  ||| S:278 E:286 ||| NN
and  ||| S:286 E:290 ||| CC
lacks  ||| S:290 E:296 ||| VBZ
significant  ||| S:296 E:308 ||| JJ
drug-drug  ||| S:308 E:318 ||| JJ
interactions  ||| S:318 E:331 ||| NNS
making  ||| S:331 E:338 ||| VBG
it  ||| S:338 E:341 ||| PRP
an  ||| S:341 E:344 ||| DT
important  ||| S:344 E:354 ||| JJ
drug  ||| S:354 E:359 ||| NN
in  ||| S:359 E:362 ||| IN
the  ||| S:362 E:366 ||| DT
treatment  ||| S:366 E:376 ||| NN
of  ||| S:376 E:379 ||| IN
a  ||| S:379 E:381 ||| DT
number  ||| S:381 E:388 ||| NN
of  ||| S:388 E:391 ||| IN
special  ||| S:391 E:399 ||| JJ
patient  ||| S:399 E:407 ||| NN
populations ||| S:407 E:418 ||| NNS
.  ||| S:418 E:420 ||| .
In  ||| S:420 E:423 ||| IN
this  ||| S:423 E:428 ||| DT
review  ||| S:428 E:435 ||| NN
its  ||| S:435 E:439 ||| PRP$
use  ||| S:439 E:443 ||| NN
in  ||| S:443 E:446 ||| IN
patients  ||| S:446 E:455 ||| NNS
undergoing  ||| S:455 E:466 ||| VBG
solid  ||| S:466 E:472 ||| JJ
organ  ||| S:472 E:478 ||| NN
and  ||| S:478 E:482 ||| CC
bone  ||| S:482 E:487 ||| JJ
marrow  ||| S:487 E:494 ||| JJ
transplantation  ||| S:494 E:510 ||| NN
and  ||| S:510 E:514 ||| CC
patients  ||| S:514 E:523 ||| NNS
receiving  ||| S:523 E:533 ||| VBG
cancer  ||| S:533 E:540 ||| NN
chemotherapy ||| S:540 E:552 ||| NN
,  ||| S:552 E:554 ||| ,
will  ||| S:554 E:559 ||| MD
be  ||| S:559 E:562 ||| VB
discussed ||| S:562 E:571 ||| VBN
.  ||| S:571 E:573 ||| .
In  ||| S:573 E:576 ||| IN
addition  ||| S:576 E:585 ||| NN
other  ||| S:585 E:591 ||| JJ
indications  ||| S:591 E:603 ||| NNS
including  ||| S:603 E:613 ||| VBG
patients  ||| S:613 E:622 ||| NNS
with  ||| S:622 E:627 ||| IN
metabolic  ||| S:627 E:637 ||| JJ
complications  ||| S:637 E:651 ||| NNS
of  ||| S:651 E:654 ||| IN
existing  ||| S:654 E:663 ||| VBG
antiretroviral  ||| S:663 E:678 ||| JJ
drugs  ||| S:678 E:684 ||| NNS
as  ||| S:684 E:687 ||| IN
well  ||| S:687 E:692 ||| RB
as  ||| S:692 E:695 ||| IN
patients  ||| S:695 E:704 ||| NNS
with  ||| S:704 E:709 ||| IN
side  ||| S:709 E:714 ||| NN
effects  ||| S:714 E:722 ||| NNS
on  ||| S:722 E:725 ||| IN
current  ||| S:725 E:733 ||| JJ
HAART  ||| S:733 E:739 ||| NNP
regimens ||| S:739 E:747 ||| NN
.  ||| S:747 E:749 ||| .
Other  ||| S:749 E:755 ||| JJ
groups  ||| S:755 E:762 ||| NNS
of  ||| S:762 E:765 ||| IN
patients  ||| S:765 E:774 ||| NNS
where  ||| S:774 E:780 ||| WRB
raltegravir  ||| S:780 E:792 ||| NNS
may  ||| S:792 E:796 ||| MD
play  ||| S:796 E:801 ||| VB
an  ||| S:801 E:804 ||| DT
important  ||| S:804 E:814 ||| JJ
role  ||| S:814 E:819 ||| NN
are  ||| S:819 E:823 ||| VBP
patients  ||| S:823 E:832 ||| NNS
with  ||| S:832 E:837 ||| IN
renal  ||| S:837 E:843 ||| JJ
disease  ||| S:843 E:851 ||| NN
and  ||| S:851 E:855 ||| CC
tuberculosis ||| S:855 E:867 ||| NN
.  ||| S:867 E:869 ||| .
Finally ||| S:869 E:876 ||| RB
,  ||| S:876 E:878 ||| ,
although  ||| S:878 E:887 ||| IN
not  ||| S:887 E:891 ||| RB
licensed  ||| S:891 E:900 ||| VBN
for  ||| S:900 E:904 ||| IN
use  ||| S:904 E:908 ||| NN
in  ||| S:908 E:911 ||| IN
pregnancy ||| S:911 E:920 ||| NN
,  ||| S:920 E:922 ||| ,
raltegravir  ||| S:922 E:934 ||| NNS
may  ||| S:934 E:938 ||| MD
need  ||| S:938 E:943 ||| VB
to  ||| S:943 E:946 ||| TO
be  ||| S:946 E:949 ||| VB
considered  ||| S:949 E:960 ||| VBN
in  ||| S:960 E:963 ||| IN
some  ||| S:963 E:968 ||| DT
pregnant  ||| S:968 E:977 ||| JJ
women  ||| S:977 E:983 ||| NNS
with  ||| S:983 E:988 ||| IN
antiretroviral  ||| S:988 E:1003 ||| JJ
resistance  ||| S:1003 E:1014 ||| NN
or  ||| S:1014 E:1017 ||| CC
tolerability  ||| S:1017 E:1030 ||| JJ
issues  ||| S:1030 E:1037 ||| NNS
with  ||| S:1037 E:1042 ||| IN
current  ||| S:1042 E:1050 ||| JJ
HAART  ||| S:1050 E:1056 ||| NNP
regimens ||| S:1056 E:1064 ||| NN
.  ||| S:1064 E:1066 ||| .
